

On page 8, line 12 delete "DNA8" and insert therefore --gDNA--.

Please amend the claims as follows:

Please cancel claims 39 and 42-43 without prejudice.

Please amend the claims as follows:

MC7  
B2  
27. A replication defective recombinant adenovirus comprising at least one DNA sequence encoding [all or an active part of] a glutathione peroxidase[, or a derivative thereof].

28. [An] The adenovirus according to claim 27, wherein the DNA sequence is a cDNA sequence.

29. [An] The adenovirus according to claim 27, wherein the DNA sequence is a [gDNA] genomic DNA sequence.

30. [An] The adenovirus according to claim 27, wherein the DNA sequence encodes a bovine glutathione peroxidase.

31. [An] The adenovirus according to claim 27, wherein the DNA sequence encodes a human glutathione peroxidase.

33. [An] The adenovirus according to claim 32, wherein the antisense sequence is an antisense RNA capable of controlling the translation of the mRNA for a glutathione peroxidase.

MC7  
34. [An] The adenovirus according to claim 27, wherein the DNA sequence is under the control of [signals] a signal controlling expression in target cells.

35. [An] The adenovirus according to claim 34, wherein the signal is a viral promoter.

B3  
MC37  
36. [An] The adenovirus according to claim 35, wherein the promoter is selected from the group consisting of E1A, MLP, CMV and RSV-LTR promoters.

37. [An] The adenovirus according to claim 27, comprising a [gDNA] genomic DNA or cDNA sequence encoding a bovine glutathione peroxidase under the control of an RSV-LTR promoter.

38. [An] The adenovirus according to claim 27, comprising a [gDNA] genomic DNA or cDNA sequence encoding a human glutathione peroxidase under the control of an RSV-LTR promoter.

40. [An] The adenovirus according to claim 39, comprising ITRs and a sequence permitting encapsidation, wherein the E1 gene and at least one of the E2, E4, or L1-L5 genes are not functional.

19/11/07  
41. [An] The adenovirus according to claim 39, wherein said adenovirus is an Ad 2 or Ad 5 human adenovirus or a CAV-2 canine adenovirus.

45. [A] The pharmaceutical composition according to claim 44, in injectable form.

135  
46. [A] The pharmaceutical composition according to claim 44, comprising between  $10^4$  and  $10^{14}$  pfu/ml of defective recombinant adenoviruses.

47. [A] The pharmaceutical composition according to claim 46, comprising between  $10^6$  to  $10^{10}$  pfu/ml of defective recombinant adenoviruses.

49. [A] The mammalian cell according to claim 48, wherein said cell is a human cell.

50. [A] The mammalian cell according to claim 49, wherein said cell is a retinal cell, fibroblast, myoblast, hepatocyte, endothelial cell, glial cell or keratinocyte.

51. An implant comprising [a] the cell according to claim 48 and an extracellular matrix.

134  
52. [An] The implant according to claim 51, wherein the extracellular matrix comprises a gelling compound.

53. [An] The implant according to claim 52, wherein the gelling compound is selected from the group consisting of collagen, gelatin, [glucosaminoglycans] a glycosaminoglycan, fibronectin, agarose and [lectins] a lectin.

54. [An] The implant according to claim 51, wherein the extracellular matrix comprises a support for anchorage of infected cells.

55. [An] The implant according to claim 54, wherein the support comprises polytetrafluoroethylene [fibres] fibers.

### REMARKS

#### Discussion of the Amended Claims

Claims 27-38, 40, 41 and 44-55 are pending in this application. Claims 42 and 43 have been canceled solely in an effort to advance prosecution.